Subject Index

Activation-induced cell death (AICD), Fas/FasL role 34–36
Adjuvant-induced arthritis
avidine-induced arthritis, rats characteristics 144
gender effects 145
Hsp60 role 145, 146
incomplete Freund’s adjuvant-induced arthritis, rats characteristics 147
genetic factors, regulation 147, 148
*Mycobacterium tuberculosis* induced arthritis, rats characteristics 141, 142
corticosteroid effects 142, 143
genome-wide linkage studies 143, 144
Hsp65 autoantigen 142, 143
overview, adjuvants 121, 123
pristane-induced arthritis mice characteristics 131, 132
genetic factors, regulation 132, 133
Hsp65, T cell responses 132
rats characteristics 146
genetic factors, regulation 146, 147
strain susceptibility
mouse 122, 123, 132, 133
rat 123–125, 141–148
AICD, see Activation-induced cell death
ALPS, see Autoimmune lymphoproliferative syndrome
Antigen-presenting cell (APC)
cytokine regulation, autoimmune disease 57, 58
Fas/FasL regulation 36–39
Antigen receptor, structure 1, 2
APC, see Antigen-presenting cell
Apoptosis, B cell germinal center response, tolerance 17, 18
Autoimmune lymphoproliferative syndrome (ALPS)
Fas/FasL mutations 39–41
pathogenesis 40, 41
Avidine, see Adjuvant-induced arthritis
B cell receptor (BCR)
editing, central tolerance 11, 13–16
Fas/FasL regulation, antigen-presenting cells 37–39
signal transduction, pre-B cell receptor 4, 6
Bcl-2, systemic lupus erythematosus role 80, 81
BCR, see B cell receptor
B lymphopoiesis
cell surface markers 4
culture systems 7
immunoglobulin gene loci, rearrangements 1–3
overview 1
signal transduction, pre-B cell receptor 4, 6
tissue distribution, fetus 3, 4
C4, systemic lupus erythematosus role
105, 107
CD22, systemic lupus erythematosus role
76, 77
CIA, see Type II collagen-induced arthritis
Collagen-induced arthritis, see Type II collagen-induced arthritis
Complement receptor type 1 (CR1), systemic lupus erythematosus role 107
Clq, systemic lupus erythematosus role
humans 100, 107
mice 79
CR1, see Complement receptor type 1
C-reactive protein (CRP), systemic lupus erythematosus role 106
CRP, see C-reactive protein
CTLA-4, systemic lupus erythematosus role
77, 78
Diabetes, see Insulin-dependent diabetes mellitus
EAE, see Experimental allergic encephalomyelitis
Experimental allergic encephalomyelitis (EAE)
active versus passive induction 249, 250
antigens, induction 250
classical genetic studies
mice 257–259
overview 255, 256
rats 256, 257
clinical features 247, 248, 250
cytokines
expression 58, 125
interferon-γ 252, 254
interleukin-12 effects 62, 252–254
Th1/Th2 cells 59, 60, 251–254
tumor necrosis factor-α 252, 254
Fas/FasL mutations 42, 43
gene expression 201
intermediate phenotype identification 264
susceptibility, inbred strains 125, 126,
256–259, 263
susceptible phenotype characterization
249–251, 264
weight loss scoring 251
Fas antigen-presenting cell regulation 36–39
gene structure 33
mutation, human disease
autoimmune lymphoproliferative
syndrome 39–41
overexpression, Hashimoto's thyroiditis
43, 44
rheumatoid arthritis 41, 42
systemic lupus erythematosus 41, 75,
81, 85
lpr mutation, mouse autoimmune models
31–33, 42, 43
T cell regulation 34–36
Fas ligand
antigen-presenting cell regulation 36–39
cleavage to yield soluble form 33, 34, 46
gld mutation, mouse autoimmune models
31–33, 42, 43
inflammatory response role 44–46
mutation, human disease
autoimmune lymphoproliferative
syndrome 39–41
rheumatoid arthritis 41, 42
systemic lupus erythematosus 41
T cell regulation 34–36
Fcy receptor cluster, systemic lupus
erythematosus role 103, 104, 107–109
Fcgr1, candidate gene, NOD mouse 220
Fibrillin-1, mutation, TSK1 mice
gene expression 201
functions of normal protein 201
partial duplication 197–199
point mutations 197–199
synthesis and secretion of protein 199, 200
transforming growth factor-β binding
201, 202
Fli-1, systemic lupus erythematosus role
83
**Subject Index**

**gld, see** Fas ligand

Grave’s disease, cytokines
expression 58
Th1 cytokine role 59, 60

H-2
H-2E, protection against type II collagen-induced arthritis 128, 129 susceptibility locus, experimental allergic encephalomyelitis 257, 258, 262

Hashimoto’s thyroiditis cytokines
expression 58
Th1 cytokine role 59, 60
Fas overexpression 43, 44

HLA-DQ, rheumatoid arthritis role 174

HLA-DR2 multiple sclerosis role 260, 262, 279, 280 systemic lupus erythematosus role 104

HLA-DR3, systemic lupus erythematosus role 104, 105

HLA-DR4, rheumatoid arthritis role 166, 173, 174, 176, 177, 183, 184
Hsp65
*Mycobacterium tuberculosis* induced arthritis role 142, 143
T cell responses, pristane-induced arthritis 132

IDDM, see Insulin-dependent diabetes mellitus

IFN-γ, see Incomplete Freund’s adjuvant
IFN-γ, see Interferon-γ

IL-1, see Interleukin-1

IL-2, see Interleukin-2

IL-4, see Interleukin-4

IL-5, see Interleukin-5

IL-6, see Interleukin-6

IL-7, see Interleukin-7

IL-10, see Interleukin-10

IL-12, see Interleukin-12

IL-13, see Interleukin-13

Immunoglobulin
allelic exclusion deficiency, autoimmunity 18, 19
gene loci, rearrangements 1–3
multiple sclerosis genes 260, 280

transgenic mouse studies
heavy-chain rearrangements 4
Ig-Tg mouse
allelic exclusion-inclusion effects 9, 10
B lymphopoiesis analysis 8, 9 principle, knock-in 7, 8
rheumatoid arthritis model 20–22 systemic lupus erythematosus model 19–21
overview, applications 1, 22
RAG knockouts 2, 4, 6, 8
tolerance, B cell compartment central tolerance 11–16 germinal center response 17, 18
peripheral tolerance 16, 17, 39

Incomplete Freund’s adjuvant (IFA), see Adjuvant-induced arthritis

Insulin-dependent diabetes mellitus (IDDM)
aminal models, overview 227

cytokines
expression 58, 65
interferon-γ role 62, 63, 65
interleukin-2, candidate gene 61, 62, 217–219
Th1 cytokine role 59–63

NOD mouse model
Fas/FasL mutations 43
interleukin-2 effects 61, 62
interleukin-12 effects 62
quantitative trait loci mapping chromosome 3 loci 214–221
congenic mapping 211–214, 216, 217, 264, 265
diversity, genes 208–211, 263, 264
*Fcg1* 220
*Id3* 216–219, 265
*Id1f10* 219–221
interleukin-2 gene, *Id3* candidate 217–219
table 209
susceptibility genes, approaches, identification 227, 228

T cell phenotypes, differences between BALB/c and B10.D2 strains
CD4 proliferation, cytokine production 234, 235
Subject Index

CD4/CD8 ratio 233–236
CD8 proliferation 234, 235
Leishmania susceptibility 233, 234
peripheral T cell numbers 233, 234
T cell receptor transgenic mouse models
BALB/c backcross resistance, Th1/Th2 responses 229–233
congenic mapping 231
cyclophosphamide effects, disease onset 241–243
MHC effects, disease susceptibility 240, 241, 243
T cell production, proliferation 237–239
T cell stimulation, disease development 232
Tira locus, CD4/CD8 skewing 236, 237
transgenes 228, 229
Interferon-γ (IFN-γ)
autoimmunity
diabetes role 62, 63, 65
role, overview 59–62
transgenic mouse studies 62, 63
experimental allergic encephalomyelitis role 252, 254
systemic lupus erythematosus role 82
Th1 expression 59
Interleukin-1 (IL-1)
rheumatoid arthritis role 64
systemic lupus erythematosus role 110
Interleukin-2 (IL-2)
autoimmunity role, overview 59–61
candidate gene, NOD mouse 217–219
NOD mouse model effects 61, 62
systemic lupus erythematosus role 79
Th1 expression 59
Interleukin-4 (IL-4)
autoimmunity role, overview 59–61, 63
systemic lupus erythematosus role 82, 83
Th2 expression 59
Interleukin-5 (IL-5)
autoimmunity role, overview 59–61, 63
Th2 expression 59
Interleukin-6 (IL-6)
autoimmunity role, overview 59–61, 63
Th2 expression 59
Interleukin-7 (IL-7), B lymphopoiesis role 6
Interleukin-10 (IL-10)
autoimmunity role, overview 59–61
systemic lupus erythematosus role 110
Th2 expression 59
Interleukin-12 (IL-12)
autoimmunity role, overview 59–61
experimental allergic encephalomyelitis role 62, 252–254
NOD mouse model effects 62
Th1 expression 59
Interleukin-13 (IL-13)
autoimmunity role, overview 59–61
Th2 expression 59
Islet cell, see Pancreatic islet cell
Lyn, systemic lupus erythematosus role 76, 77
Mannose-binding protein, systemic lupus erythematosus role 105, 106
Multiple sclerosis (MS), see also Experimental allergic encephalomyelitis
adoption studies 277
clinical features 273, 274
cytokines
expression 58
Th1 cytokine role 59, 60
diagnosis 273, 274
familial aggregation 275, 276
population prevalence 274, 275
recurrence risk ratio 275
segregation analysis 277
susceptibility genes
candidate gene analysis 278, 279
gene-wide screening, susceptibility loci 262, 280–282
HLA regions 260, 262, 279, 280
immunoglobulin genes 260, 280
interactions, genes 284
mapping, Human Genome Project sequences 283
myelin basic protein 260, 280
twin studies 259, 276, 277
Subject Index

Myelin basic protein
experimental allergic encephalomyelitis
role 259, 261
multiple sclerosis role 260, 280

NOD mouse, see Insulin-dependent diabetes mellitus

Pancreatic islet cell, FasL transduction,
allogeneic recipient rejection 44, 45

Pim-1, systemic lupus erythematosus role
83, 84

lpr, see Fas

Pristane, see Adjuvant-induced arthritis

RA, see Rheumatoid arthritis

RAG, see Recombinase activator gene

Recombinase activator gene (RAG),
transgenic mouse knockouts 2, 4, 6, 8

Rheumatoid arthritis (RA)
cytokines
expression 58, 63, 64
Th2 cytokine role 59, 60, 64
diagnostic criteria 172, 173, 178, 179
experimental induction, rodents, see
Adjuvant-induced arthritis,
Streptococcal cell wall-induced arthritis,
Type II collagen-induced arthritis
Fas/FasL mutations 41, 42, 75
genetic model reflecting germline and
somatic genome interactions 170–172
heredity
familial clustering 169, 174, 175
twin studies 168, 169

mouse models
MRL/lpr mouse 20
(NZB × NZW)F1 mice 20
transgenic mice 20–22
pathogenesis, challenges in study
167, 182, 183
susceptibility genes
association studies 185
candidate gene testing 187, 188
HLA markers, severity 177, 178
HLA-DQ 174
HLA-DR4 166, 173, 174, 176, 177,
183, 184

linkage analysis 184, 185
pedigree analysis 189
problems in deciphering HLA role
diagnosis uncertainty 178, 179
disease paradigm selection 179, 180
pathogenesis 182, 183
shared epitope alleles, lacking 182
somatic genomics, degenerate
recognition 180–182
shared epitope hypothesis 175–177,
180–182
tumor necrosis factor-α 183
whole genome screens 186, 187

RT1, susceptibility locus, rat experimental
allergic encephalomyelitis 256, 257

Scleroderma
extracellular matrix protein deposition
194
inducible animal models 194
tight skin mouse models
autoantibodies 196
fibrillin-1 mutation, TSK1 mice
functions, normal protein 201
genotyping, polymerase chain
reaction 197, 198
inheritance, cutaneous hyperplasia
200, 201
partial duplication 197–199
point mutations 197–199
synthesis, secretion of protein
199, 200
transforming growth factor-β binding
201, 202
gene loci, transmission 194, 196
phenotype 195, 196
T cell role 202–204

SHP-1, systemic lupus erythematosus role
76

SLE, see Systemic lupus erythematosus
Streptococcal cell wall-induced arthritis
characteristics 148
genetic factors, regulation 148, 149
susceptibility, rat strains 148, 149
Systemic lupus erythematosus (SLE)
association studies in humans 104
autoantibody types 99
cytokines
expression 58
interferon-γ role 63, 82
interleukins role 79, 82, 83, 110
Th2 cytokine role 59
transforming growth factor-β role 78, 79
tumor necrosis factor role 78, 109, 110
diversity of genes, pathogenesis 91, 100
gene roles, humans
Bel-2 111
C4 105, 107
cell signaling genes 111, 112
complement receptor type 1 107
Clq 100, 107
C-reactive protein 106
Fas/FasL 111
Fcγ receptor cluster 103, 104, 107–109
HLA-DR2 104
HLA-DR3 104, 105
interleukin-1 110
interleukin-10 110
mannose-binding protein 105, 106
T cell receptor polymorphisms 105
tumor necrosis factor 109, 110
gene roles, mice
Bel-2 80, 81
CD22 76, 77
Clq 79
CTLA-4 77, 78
Fas/FasL 31–33, 41, 75, 81, 85
Fli-1 83
interferon-γ 82
interleukin-2 79
interleukin-4 82, 83
lyn 76, 77
pim-1 83, 84
SHP-1 76
transforming growth factor-β 78, 79
tristetraprolin 78
tumor necrosis factor receptor 78
Yaa gene 75
heredity 72, 73, 99, 100, 168, 169
linkage studies, susceptibility loci
humans 101, 103, 112
mice 85–90, 102, 103
mouse models
gene knockout models 76–79

MRL/lpr mouse 31–33, 41
NZB × NZW 88–90, 102, 263, 264
spontaneous models 75, 76, 102
tables 74, 75
transgenic mice 19–21, 79–85
prevalence 72

T cell
activation-induced cell death, Fas/FasL role 34–36
cytokines
autoimmunity, role of Th1 and Th2 cytokines 59–61, 252–255
expression, subsets 58, 59, 252
response, overview 57
experimental allergic encephalomyelitis role, Th1/Th2 cells 59, 60, 251–254
phenotype differences between BALB/c and B10.D2 strains
CD4 proliferation, cytokine production 234, 235
CD4/CD8 ratio 233–236
CD8 proliferation 234, 235
Leishmania susceptibility 233, 234
peripheral T cell numbers 233, 234
somatic genetic diversity, repertoire 170
tight skin mouse syndrome role 202–204
T cell receptor (TCR)
experimental allergic encephalomyelitis, β-chain role, susceptibility 259
systemic lupus erythematosus polymorphisms 105
transgenic mouse models, diabetes
BALB/c backcross resistance, Th1/Th2 responses 229–233
congenic mapping 231
cyclophosphamide effects, disease onset 241–243
MHC effects, disease susceptibility 240, 241, 243
T cell production, proliferation 237–239
T cell stimulation, disease development 232
T cell locus, CD4/CD8 skewing 236, 237
transgenes 228, 229
TCR, see T cell receptor
TDT, see Transmission disequilibrium test
TGF-β, see Transforming growth factor-β
Tight skin mouse (TSK), see Scleroderma
TNF-α, see Tumor necrosis factor-α
TNF-β, see Tumor necrosis factor-β
Tolerance, transgenic mouse studies, B cell compartment
central tolerance 11–16
germinal center response 17, 18
peripheral tolerance 16, 17, 39
Transforming growth factor-β (TGF-β), systemic lupus erythematosus role 78, 79
Transgenic mouse
B cell studies
heavy chain rearrangements 4
Ig-Tg mouse
allelic exclusion-inclusion effects 9, 10
B lymphopoiesis analysis 8, 9
principle, knock-in 7, 8
rheumatoid arthritis model 20–22
systemic lupus erythematosus model 19–21
overview, applications 1, 22
RAG knockouts 2, 4, 6, 8
tolerance, B cell compartment
central tolerance 11–16
germinal center response 17, 18
peripheral tolerance 16, 17
interferon-γ 62, 63
T cell receptor
diabetes models
BALB/c backcross resistance, Th1/Th2 responses 229–233
congenic mapping 231
cyclophosphamide effects, disease onset 241–243
MHC effects, disease susceptibility 240, 241, 243
T cell production, proliferation 237–239
T cell stimulation, disease development 232

Tcr locus, CD4/CD8 skewing
transgenes 228, 229
studies, activation-induced cell death 35, 36
Transmission disequilibrium test (TDT), multiple sclerosis 284
Tristetraprolin (TTP), systemic lupus erythematosus role 78
TSK, see Tight skin mouse
TTP, see Tristetraprolin
Tumor necrosis factor-α (TNF-α)
experimental allergic encephalomyelitis role 252, 254
rheumatoid arthritis role 64, 183
systemic lupus erythematosus role 109, 110
Tumor necrosis factor-β (TNF-β)
autoimmunity role, overview 59–61
systemic lupus erythematosus role 109, 110
Th1 expression 59
Tumor necrosis factor receptor, systemic lupus erythematosus role 78
Type II collagen-induced arthritis (CIA)
cytokine expression 127, 134
 genetic factors, regulation
mice
gender, hormonal influences 131
H-2E 128, 129
HLA transgenic mice 127–129
rats
gene homology analysis, mouse and human 136–140
MHC genes 135, 136, 138
non-MHC genes 136, 138
quantitative trait locus analysis 135, 136–140
inbred strain susceptibility
mouse 122, 123, 127, 129, 130
rat 123–125, 133–136
pathogenesis 126, 127, 133, 134
principle, induction 121
Yaa, systemic lupus erythematosus role 75

Subject Index